SCHEMBL33530580

SCHEMBL33530580

COc1cc(-c2cn(C)c(=O)c(C)c2C)cc(OC)c1CN1C[C@H](C)N(C(=O)OC(C)(C)C)C[C@@H]1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 12/20 0.48
BRD4 O60885 9/20 0.48
BRD7 Q9NPI1 9/20 0.48
BRD2 P25440 5/20 0.48
CYP3A4 P08684 1/20 0.35
TBK1 Q9UHD2 1/20 0.35
SUV39H2 Q9H5I1 2/20 0.33
MAPK14 Q16539 2/20 0.33
TAF1 P21675 1/20 0.33
TGFBR1 P36897 1/20 0.33
BRPF1 P55201 1/20 0.33
ACVR1 Q04771 1/20 0.33
BPTF Q12830 1/20 0.33
TAF1L Q8IZX4 1/20 0.33
CREBBP Q92793 1/20 0.33
CECR2 Q9BXF3 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
ATAD2B Q9ULI0 1/20 0.33
CD274 Q9NZQ7 1/20 0.32
SETD7 Q8WTS6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33530798 1.00 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33532097 1.00 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33532877 1.00 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33532700 0.88 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33531804 0.88 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33532825 0.85 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33531659 0.85 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33533083 0.85 BRD9 (0.51) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33532986 0.84 BRD4 (0.50) BRD9BRD4BRD7BRD2CYP3A4
SCHEMBL33532831 0.83 BRD9 (0.48) BRD9BRD4BRD7BRD2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 BRD9 3/4885BRD4 161/4885BRD7 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.